National Cancer Institute blog, by Lindsay Harris, MD
NCI-MATCH, the largest precision medicine trial of its kind, was launched in August 2015 by NCI and the ECOG-ACRIN Cancer Research Group. Initial findings from several of the trial’s treatment arms—in effect, sub-studies of the larger trial that are testing specific therapies—have been released over the last year.
But, as is to be expected in a dynamic trial of this size and scope, much more is happening.
This includes the opening of new trial treatment arms that are testing additional drugs, and the addition of new laboratories to perform testing on tumor samples of potential trial participants.
Given the extent of the activity and the importance of this trial, we’d like to update the cancer community on the status of NCI-MATCH and share the plans for it going forward.